Unsere Publikationen

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Link
https://doi.org/10.57264/cer-2023-0161
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
Verlag
J Comp Eff Res. 2024 Aug 19:e230161.
Zum Eintrag

Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER

Link
https://doi.org/10.1016/j.msard.2024.105812
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Ziemssen T, Posevitz-Fejfár A, Chudecka A, Cepek L, Reifschneider G, Grothe C, Richter J, Wagner T, Müller B, Penner IK.
Verlag
Mult Scler Relat Disord. 2024 Aug 10;90:105812.
Zum Eintrag

Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA

Link
https://doi.org/10.1016/j.nerep.2024.100211
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Yalachkov Y, Akgün K, Ziemssen T.
Verlag
Neuroimmunology Reports. 2024, 5:100211.
Zum Eintrag

Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis

Link
https://doi.org/10.1016/j.msard.2024.105751
Tags
Multiple SkleroseMS BehandlungManagement & Science
Jahr
2024
Autoren
Papukchieva S, Kim HD, Stratil AS, Magurne E, Jonckheere A, Kahn M, Schneeweiss S, Ziemssen T, Friedrich B.
Verlag
Mult Scler Relat Disord. 2024 Jul 4;88:105751.
Zum Eintrag

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Link
https://doi.org/10.3389/fimmu.2024.1404316
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Höpner L, Proschmann U, Inojosa H, Ziemssen T, Akgün K.
Verlag
Front Immunol. 2024 Jun 13;15:1404316.
Zum Eintrag

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Link
https://doi.org/10.1007/s40120-024-00637-2
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Singer BA, Wray S, Gudesblatt M, Bumstead B, Ziemssen T, Bonnell A, Scaramozza M, Levin S, Shanmugasundaram M, Chen H, Mendoza JP, Lewin JB, Shankar SL.
Verlag
Neurol Ther. 2024 Jun 27.
Zum Eintrag

Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis

Link
https://doi.org/10.1002/brb3.3498
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Müller J, Roos I, Kalincik T, Lorscheider J, Galli E, Benkert P, Schädelin S, Sharmin S, Einsiedler M, Hänni P, Schmid J, Kuhle J, Derfuss T, Granziera C, Ziemssen T, Siepmann T, Yaldizli Ö.
Verlag
Brain Behav. 2024 May;14(5):e3498.
Zum Eintrag

Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App

Link
https://doi.org/10.3390/jpm14040409
Tags
Multiple SkleroseMS BehandlungeHealth
Jahr
2024
Autoren
Papukchieva S, Kahn M, Eberl M, Friedrich B, Joschko N, Ziemssen T.
Verlag
Journal of Personalized Medicine. 2024; 14(4):409.
Zum Eintrag
1 2 3 4 5

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-